BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
BioXcel Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 53.1%. For fiscal 2025 it was 74.5%, against 5.4% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.5% | +69.0 |
| FY2024 | Dec 31, 2024 | 5.4% | −3.3 |
| FY2023 | Dec 31, 2023 | 8.7% | −86.0 |
| FY2022 | Dec 31, 2022 | 94.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 87.9% | +77.1 |
| Q1 FY2026 | Mar 31, 2026 | -37.4% | −129.0 |
| Q4 FY2025 | Dec 31, 2025 | 87.5% | +214.8 |
| Q3 FY2025 | Sep 30, 2025 | 88.8% | +535.5 |
| Q2 FY2025 | Jun 30, 2025 | 10.8% | −83.6 |
| Q1 FY2025 | Mar 31, 2025 | 91.7% | +5.4 |
| Q4 FY2024 | Dec 31, 2024 | -127.3% | −37.4 |
| Q3 FY2024 | Sep 30, 2024 | -446.7% | −396.6 |
| Q2 FY2024 | Jun 30, 2024 | 94.4% | +0.1 |
| Q1 FY2024 | Mar 31, 2024 | 86.3% | −9.4 |
| Q4 FY2023 | Dec 31, 2023 | -89.9% | −186.1 |
| Q3 FY2023 | Sep 30, 2023 | -50.1% | −142.1 |
| Q2 FY2023 | Jun 30, 2023 | 94.3% | – |
| Q1 FY2023 | Mar 31, 2023 | 95.6% | – |
| Q4 FY2022 | Dec 31, 2022 | 96.2% | – |
| Q3 FY2022 | Sep 30, 2022 | 92.0% | – |
See a number that looks wrong?